Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Amgen's annualizedNet Income for the quarter that ended in Sep. 2023 was $6,920 Mil. Amgen's average total tangible assets for the quarter that ended in Sep. 2023 was $60,990 Mil. Therefore, Amgen's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 was 11.35%.
The historical rank and industry rank for Amgen's Return-on-Tangible-Asset or its related term are showing as below:
AMGN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.63 Med: 16.34 Max: 25.37
Current: 15.2
During the past 13 years, Amgen's highest Return-on-Tangible-Asset was 25.37%. The lowest was 3.63%. And the median was 16.34%.
AMGN's Return-on-Tangible-Asset is ranked better than 91.27% of 1100
companies
in the Drug Manufacturers industry
Industry Median: 1.83
vs AMGN: 15.20
Amgen Return-on-Tangible-Asset Historical Data
The historical data trend for Amgen's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Return-on-Tangible-Asset
16.65
22.45
25.37
18.78
20.28
Amgen Quarterly Data
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Return-on-Tangible-Asset
25.94
18.71
24.89
9.36
11.35
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Return-on-Tangible-Asset Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Amgen's Return-on-Tangible-Asset falls into.
Amgen Return-on-Tangible-Asset Calculation
Amgen's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Sep. 2023) net income data.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Amgen Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of Amgen's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
3.04(1.14%) Volume: 2,499,855 4:00PM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
AMGN has been successfully added to your 